Volume 3.24 | Jun 19

Hematopoiesis News 3.24 June 19, 2012
Hematopoiesis News
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Lysine-Specific Demethylase 1 Restricts Hematopoietic Progenitor Proliferation and Is Essential for Terminal Differentiation
Researchers showed with a newly established conditional in vivo knockdown model that lysine-specific demethylase 1 represents a central regulator of hematopoietic stem and progenitor cells. [Leukemia] Abstract

Complimentary Wallchart: Human Hematopoietic Progenitors. Request Your Copy Today.
PUBLICATIONS (Ranked by impact factor of the journal)


Exome Sequencing Identifies GATA1 Mutations Resulting in Diamond-Blackfan Anemia
These findings provide insight into the pathogenesis of Diamond-Blackfan anemia, showing that the reduction in erythropoiesis associated with the disease can arise from causes other than defects in ribosomal protein genes. These results also illustrate the multifactorial role of GATA1 in human hematopoiesis. [J Clin Invest] Full Article

Genome-Wide DNA Methylation Profiles in Hematopoietic Stem and Progenitor Cells Reveal Over-Representation of ETS Transcription Factor Binding Sites
To better understand the role of DNA methylation in hematopoiesis, we characterized genome-wide DNA methylation in primary mouse hematopoietic stem cells, common myeloid progenitors, and erythroblasts. [Genome Res] Abstract

Stable Long-Term Blood Formation by Stem Cells in Murine Steady-State Hematopoiesis
This study represents the first continuous analysis of clonal behavior of genetically marked hematopoietic cells in an unmanipulated system, providing evidence that multiple clones are simultaneously active in murine steady-state hematopoiesis. [Stem Cells] Abstract

MYC Antagonizes the Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells through Downregulation of p27KIP1
The results suggest that, although MYC deregulation does not directly confer resistance to imatinib, it might be a factor that contributes to progression of chronic myeloid leukemia through the inhibition of differentiation. [Oncogene] Abstract

Distinctive Contact between CD34+ Hematopoietic Progenitors and CXCL12+ CD271+ Mesenchymal Stromal Cells in Benign and Myelodysplastic Bone Marrow
Scientists analyzed putative mesenchymal stromal cell markers and their relationship to CD34+ hematopoietic stem/progenitor cells within intact human bone marrow in paraffin-embedded bone marrow core biopsies of benign, myelodysplastic syndrome and leukemic marrows using tissue microarrays to facilitate scanning, image analysis and quantitation. [Lab Invest] Abstract

Adenosine Receptor A2b on Hematopoietic Cells Mediates LPS-Induced Migration of Polymorphonuclear Leukocytes into the Lung Interstitium

The results demonstrate anti-inflammatory effects of A2b on two major characteristics of acute lung injury, with a distinct role of hematopoietic A2b for cell trafficking and endothelial A2b for microvascular permeability. [Am J Physiol Lung Cell Mol Physiol] Abstract

Inhibition of Erythropoiesis by Smad6 in Human Cord Blood Hematopoietic Stem Cells
Researchers suggest that Smad6 indirectly maintains stemness by preventing spontaneous erythropoiesis in hematopoietic stem cells. [Biochem Biophys Res Commun] Abstract


All-Trans-Retinoic Acid, Idarubicin, and Intravenous Arsenic Trioxide as Initial Therapy in Acute Promyelocytic Leukemia
The treatment of acute promyelocytic leukemia has improved considerably following recognition of the effectiveness of all-trans-retinoic acid, anthracycline-based chemotherapy, and arsenic trioxide. Researchers report the use of all three agents in combination. [Blood] Abstract

Allogeneic Hematopoietic Stem Cell Transplantation for Adult AML Patients with Granulocytic Sarcoma
Investigators assessed the efficacy of allogeneic hematopoietic stem cell transplantation for the management of acute myeloid leukemia (AML) with granulocytic sarcoma. [Leukemia] Abstract

Elacytarabine Has Single-Agent Activity in Patients with Advanced Acute Myeloid Leukemia
This Phase II study assessed the efficacy and safety of elacytarabine in patients with advanced stage acute myeloid leukemia. [Br J Haematol] Abstract

Read White Paper: Increase Success Rate Of Compounds In Toxicity Testing


Pharmacyclics® Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765)
Pharmacyclics, Inc announced updated results from two clinical trials of Bruton’s tyrosine kinase (BTK) inhibitor, PCI-32765, for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. [Press release from Pharmacyclics, Inc. discussing research presented at the 17th Congress of the European Hematology Association (EHA), Amsterdam] Press Release

Acute Lymphocytic Leukemia: Impressive Results with the Monoclonal Antibody Blinatumomab in Patients with Refractory Disease
The Phase II dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor acute lymphoblastic leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant. [Press release from PR Newswire discussing research presented at the 17th Congress of the European Hematology Association (EHA), Amsterdam] Press Release


bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy
bluebird bio announced that both the U.S. Food and Drug Administration and the European Medicines Agency have granted an orphan drug designation to its investigational gene therapy product for the treatment of adrenoleukodystrophy. The product consists of the patient’s own CD34+ hematopoietic stem cells transduced with bluebird bio’s lentiviral vector encoding the human ABCD1 cDNA. [bluebird bioTM]
Press Release

Cellerant Appoints Gisela Schwab to Its Board of Directors and Names Lowell Sears as Chairman of the Board
Cellerant Therapeutics Inc. announced the appointment of Gisela Schwab to its Board of Directors and the appointment of Lowell Sears as Chairman of the Board. [Cellerant Therapeutics Inc.] Press Release

Study of Cell Therapeutics’ Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
Cell Therapeutics, Inc. announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. [Cell Therapeutics, Inc.] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW National Hemophilia Foundation’s 64th Annual Meeting: Mapping Our Future
November 8-10, 2012
Orlando, United States
Visit our events page to see a complete list of events in the hematopoietic community.


Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Postdoctoral Fellowship – Cellular Origin of Blood Cells (European Molecular Biology Laboratory)

PhD Position – Construction of a Biomimetic, Hematopoietic Stem Cell Niche (Karlsruhe Institute of Technology – Helmholtz Association)

Postdoctoral Position – Hematopoietic Stem Cell Biology and Immunology (University of California, San Francisco)

Postdoctoral Position – Hematopoietic Lineage Commitment and Leukemia Development (University of Oxford – Weatherall Institute of Molecular Medicine)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us